Search Results
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain
Search for other papers by Pedro Iglesias in
Google Scholar
PubMed
Unit of Nutrition and Cancer-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
Search for other papers by Inmaculada Peiró in
Google Scholar
PubMed
Search for other papers by Betina Biagetti in
Google Scholar
PubMed
Search for other papers by Miguel Paja-Fano in
Google Scholar
PubMed
Search for other papers by Diana Ariadel Cobo in
Google Scholar
PubMed
Search for other papers by Carlos García Gómez in
Google Scholar
PubMed
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain
Search for other papers by Manuel Mateu-Salat in
Google Scholar
PubMed
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain
Search for other papers by Idoia Genua in
Google Scholar
PubMed
Search for other papers by Margarita Majem in
Google Scholar
PubMed
Search for other papers by Mariona Riudavets in
Google Scholar
PubMed
Search for other papers by Javier Gavira in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Search for other papers by Antía Fernández Pombo in
Google Scholar
PubMed
Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed
Search for other papers by Carles Villabona in
Google Scholar
PubMed
Search for other papers by José Manuel Cabezas Agrícola in
Google Scholar
PubMed
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Universitat Autònoma de Barcelona, Barcelona, Spain
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain
Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
Search for other papers by Juan J Díez in
Google Scholar
PubMed
Introduction Checkpoint inhibitor immunotherapy has been shown to be an effective therapy in a wide variety of malignant tumors, such as advanced melanoma, renal carcinoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma
Peptide Hormones Supraregional Assay Service (SAS), Faculty of Health and Medical Sciences, Clinical Biochemistry Department, Royal Surrey County Hospital NHS Trust, Guildford, Surrey GU2 7XX, UK
Search for other papers by Callum Livingstone in
Google Scholar
PubMed
significant advances in recent years. The purpose of this review is to provide the reader with a perspective and update on IGF2, with respect to its role in cancer and clinical utility for its measurement. The IGFs are part of a complex system, the components
Search for other papers by Sock Hoai Chan in
Google Scholar
PubMed
Oncology Academic Clinical Program, Duke-NUS Medical School Singapore, Singapore
Search for other papers by Joanne Ngeow in
Google Scholar
PubMed
Introduction Genomic instability is a hallmark of human cancers ( Negrini et al. 2010 ). It refers to the increased frequency of accruing genetic alterations, ranging from single nucleotide mutations to whole chromosome changes such as
Search for other papers by David L Vesely in
Google Scholar
PubMed
2003 , Cataliotti & Burnett 2005 ). When these four cardiac hormones synthesized by the ANP prohormone gene are given in concentrations higher than those synthesized by the heart, they have anticancer effects on human pancreatic cancers growing in
Search for other papers by Massimo Terzolo in
Google Scholar
PubMed
Search for other papers by Giuseppe Reimondo in
Google Scholar
PubMed
Search for other papers by Paola Berchialla in
Google Scholar
PubMed
Search for other papers by Emanuele Ferrante in
Google Scholar
PubMed
Search for other papers by Elena Malchiodi in
Google Scholar
PubMed
Search for other papers by Laura De Marinis in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Marco Losa in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavo in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Marcella Montini in
Google Scholar
PubMed
Search for other papers by Marta Bondanelli in
Google Scholar
PubMed
Search for other papers by Ernesto De Menis in
Google Scholar
PubMed
Search for other papers by Chiara Martini in
Google Scholar
PubMed
Search for other papers by Efisio Puxeddu in
Google Scholar
PubMed
Search for other papers by Antonino Velardo in
Google Scholar
PubMed
Search for other papers by Alessandro Peri in
Google Scholar
PubMed
Search for other papers by Marco Faustini-Fustini in
Google Scholar
PubMed
Search for other papers by Patrizia Tita in
Google Scholar
PubMed
Search for other papers by Francesca Pigliaru in
Google Scholar
PubMed
Search for other papers by Giulia Peraga in
Google Scholar
PubMed
Search for other papers by Giorgio Borretta in
Google Scholar
PubMed
Search for other papers by Carla Scaroni in
Google Scholar
PubMed
Search for other papers by Nicoletta Bazzoni in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Search for other papers by Alessandro Berton in
Google Scholar
PubMed
Search for other papers by Andreea Liliana Serban in
Google Scholar
PubMed
Search for other papers by Roberto Baldelli in
Google Scholar
PubMed
Search for other papers by Letizia Maria Fatti in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Maura Arosio in
Google Scholar
PubMed
Search for other papers by for the Italian Study Group of Acromegaly in
Google Scholar
PubMed
Italian patients and found that vascular disease and cancer were the main causes of death. Mortality was higher in patients with persistently active disease, and IGF1 levels at diagnosis, GH at the last follow-up, cancer and pituitary radiotherapy were
Search for other papers by Annemiek Walenkamp in
Google Scholar
PubMed
Search for other papers by Guillermo Crespo in
Google Scholar
PubMed
Search for other papers by Felipe Fierro Maya in
Google Scholar
PubMed
Search for other papers by Reidar Fossmark in
Google Scholar
PubMed
Search for other papers by Peter Igaz in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Gianluca Tamagno in
Google Scholar
PubMed
Department of Medical Oncology, Department of Medical Oncology, Department of Endocrine Oncology, Department of Cancer Research and Molecular Medicine, 2nd Department of Medicine, Department of Gastroenterology, Department of General Internal Medicine, Department of Clinical Sciences and Community Health (DISCCO), Laboratory of Endocrine and Metabolic Research, Department of Endocrine Oncology, UCL Cancer Institute, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Tim Meyer in
Google Scholar
PubMed
Introduction Neuroendocrine tumours (NETs) are diverse in their site of origin and clinical behaviour, ranging from highly aggressive small cell cancers of the lung to indolent, low-grade tumours of the small bowel ( Yao et al . 2008 a ). Symptoms
Instituto de Endocrinología IEMYR, Quito, Ecuador
Maastricht University, Maastricht, The Netherlands
Search for other papers by Jaime Guevara-Aguirre in
Google Scholar
PubMed
Search for other papers by Gabriela Peña in
Google Scholar
PubMed
Search for other papers by Gabriel Pazmiño in
Google Scholar
PubMed
Search for other papers by William Acosta in
Google Scholar
PubMed
Search for other papers by Jannette Saavedra in
Google Scholar
PubMed
Search for other papers by Daniela Lescano in
Google Scholar
PubMed
Search for other papers by Alexandra Guevara in
Google Scholar
PubMed
Search for other papers by Antonio W D Gavilanes in
Google Scholar
PubMed
incidence of cancer despite obesity as a risk factor. As noted, while the most striking clinical association observed in the ELS subjects is that of obesity and low T2D incidence, the diminished incidence of malignancies despite the risk factor posed by
Search for other papers by James F H Pittaway in
Google Scholar
PubMed
Search for other papers by Constantinos Lipsos in
Google Scholar
PubMed
Search for other papers by Katia Mariniello in
Google Scholar
PubMed
Search for other papers by Leonardo Guasti in
Google Scholar
PubMed
with differential expression in small cell lung cancer cell lines. Structural analysis of the protein revealed it was highly homologous with the proteins Delta , Serrate and Notch from Drosophila melanogaster and it was termed ‘human Delta
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria
Search for other papers by Francesca Ruggieri in
Google Scholar
PubMed
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria
Search for other papers by Katharina Jonas in
Google Scholar
PubMed
Search for other papers by Manuela Ferracin in
Google Scholar
PubMed
Search for other papers by Michael Dengler in
Google Scholar
PubMed
Search for other papers by Vanessa Jӓger in
Google Scholar
PubMed
Research Unit “Non-Coding RNAs and Genome Editing in Cancer”, Division of Oncology, Medical University of Graz, Graz, Austria
Department of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany
Translational Oncology, University Hospital of Augsburg, Augsburg, Germany
Search for other papers by Martin Pichler in
Google Scholar
PubMed
Introduction At the beginning of the twenty-first century, Hanahan and Weinberg described some essential capabilities (hallmarks of cancer) which tumor cells have to acquire and which collectively drive malignant growth ( Hanahan & Weinberg
CiberOnc, Instituto de Salud Carlos III, Madrid, Spain
Search for other papers by Antonio De la Vieja in
Google Scholar
PubMed
Department of Physiopathology of Endocrine a Nervous System, Instituto de Investigaciones Biomédicas ‘Alberto Sols’, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain
Search for other papers by Pilar Santisteban in
Google Scholar
PubMed
thyroid dysfunction and thyroid cancer ( Pfinder et al . 2016 ). On the other hand, radioactive iodine (RAI) therapy with 131 I has been the cornerstone adjuvant therapy for the treatment of thyroid cancer for decades ( Seidlin et al . 1946 ), with